Treatment of Moderate to Severe Atopic Dermatitis

Eligibility Details: Inclusion Criteria: - Participant has active moderate to severe atopic dermatitis (AD) defined by Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Body Surface Area (BSA) and pruritus. - Participant is a candidate for systemic therapy or have recently required systemic therapy for AD. Exclusion Criteria: - Participant has prior exposure to Janus Kinase (JAK) inhibitor. - Participant has prior exposure to dupilumab. - Participant is unable or unwilling to discontinue current AD treatments prior to the study. - Participant has requirement of prohibited medications during the study. - Participant has other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of AD lesions. - Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.